HHS In role

Roger Klein

Director, Agency for Healthcare Research and Quality (AHRQ)

Physician-lawyer (M.D., J.D.) — a board-certified molecular pathologist and former chief medical officer of the tumor-profiling company OmniSeq — serving since July 2025 as the seventh Director of AHRQ, the federal health-services research agency. He leads a much-reduced agency whose grantmaking halt GAO later found unlawful, while refocusing its mission on patient safety, measurable outcomes, and AI-driven evidence synthesis.

Director, Agency for Healthcare Research and Quality (AHRQ)
AHRQ's survival and refocus: grantmaking, evidence synthesis, patient safety, and USPSTF oversight
Confirmed:
Wins
0
Pending
0
Setbacks
0

Role status — October 2026: Klein is the seventh Director of the Agency for Healthcare Research and Quality, in the role since July 2025. The job is filled by the HHS Secretary rather than by Senate confirmation, and Klein — succeeding acting director Mamatha Pancholi — was still signing agency announcements as director in October 2026.

Klein is a physician-lawyer with a laboratory career. A board-certified molecular pathologist, he was chief medical officer of OmniSeq, a tumor-profiling company acquired by LabCorp, and medical director of molecular pathology at several academic institutions, including Cleveland Clinic, where he oversaw molecular oncology and germline genetic testing. He trained at Case Western Reserve (medical school), Yale (residency and fellowships), and the Mayo Clinic (fellowship), and earned his law degree at Yale Law School. He has advised HHS, FDA, CMS, and CDC, held leadership roles in pathology and oncology professional societies, and lists policy affiliations including the Regulatory Transparency Project and the Heartland Institute.

His directorship is inseparable from his agency’s near-death experience. In March 2025 Secretary Kennedy announced AHRQ would be merged with the planning office ASPE into a new Office of Strategy, and a reduction in force followed: more than 120 employees were separated on July 14, 2025, the month Klein took over, and later reporting put the agency at roughly 74–90 staff versus about 300 in early 2025. Congress ultimately kept AHRQ’s structure and most of its budget ($345 million for FY2026), but its grantmaking largely stopped — and on October 7, 2026, the GAO found HHS had violated the Impoundment Control Act by withholding AHRQ grant funds without notifying Congress. Klein has defended a refocused mission: his January 2026 priorities statement argued too much funding had gone to “equity and DEI” and emphasized patient safety and measurable outcomes, while former employees told Roll Call he had held back agency communications and reports — characterizations HHS disputed. In May 2026 Kennedy formally delegated day-to-day oversight of the U.S. Preventive Services Task Force to the AHRQ director, and in October 2026 Klein launched a pair of prize programs — an $11.8 million challenge on health-care competition and a $7.95 million “Super Intelligence” initiative for AI-driven clinical evidence synthesis.

Why tracked here: Klein is the official deciding what AHRQ becomes after its dismantling attempt — whether the federal government’s health-services research agency keeps publishing evidence, running the preventive-services pipeline, and funding outside researchers, or narrows to a smaller, prize-driven shop.

Sources (Oct 2026): AHRQ director bio and mission pages; 42 U.S.C. § 299; GAO Decision B-337872, Oct. 7, 2026; Science (2026); Becker’s Hospital Review, Apr. 2026; Federal Register delegation, May 2026; AHRQ releases via PR Newswire, Oct. 6–7, 2026.

The Weekly Scoreboard

Every Friday: what the RFK Jr. HHS team did this week — wins, setbacks, warnings — sourced and linked. Free.

One email a week. No spam. Unsubscribe anytime. · Follow on Facebook

The Network — One Publisher, Every Front
Published by Bowman Web Services.